Heron Therapeutics Inc vs iShares 1 3 Year Treasury Bond ETF — how do they compare? Heron Therapeutics Inc trades at $0.36 (market cap $68.01M), while iShares 1 3 Year Treasury Bond ETF trades at $81.21 (market cap $26.68B). The key difference: iShares 1 3 Year Treasury Bond ETF is far larger — about 392.3× Heron Therapeutics Inc's market cap, and iShares 1 3 Year Treasury Bond ETF is more actively traded (4,077,691 versus 1,891,941). Which is the better fit depends on your goals — on Pluang, investors hold Heron Therapeutics Inc for 35 Days and iShares 1 3 Year Treasury Bond ETF for 63 Days on average.
| HRTX | SHY | |
|---|---|---|
Market Cap | $68.01M | $26.68B |
Volume | 1,891,941 | 4,077,691 |
Sector | Health | Fixed Income |
52-Week High | $1.49 | $83.18 |
52-Week Low | $0.27 | $81.05 |
Typical Hold Time | 35 Days | 63 Days |
Enterprise Value | $174.75M | — |
Signals from Pluang's Aura AI — not financial advice
Heron Therapeutics (HRTX) is trading at $0.39, up 17.58% today, with a bullish technical outlook from moving averages but mixed signals from oscillators. The company maintains strong gross margins of 70.07% but continues to report net losses, with Q2 2026 missing both EPS and revenue expectations. Analyst sentiment remains overwhelmingly positive with 89% buy ratings despite recent earnings disappointments and negative profitability metrics.
While analyst consensus is strongly bullish, HRTX faces significant fundamental challenges including consistent net losses, negative ROE of -78.72%, and cash flow concerns. The stock's current momentum appears driven by technical factors rather than improving fundamentals, creating a high-risk investment profile that requires careful monitoring of upcoming Q3 earnings and revenue stabilization efforts.
SHY, a US stock, trades at $81.16, up 0.04% on the day. Technical indicators are bearish, with moving averages signaling sell pressure and oscillators neutral. The stock faces resistance and support near $81. Recent corporate actions include dividend payments, with the latest at $0.24 per share. Financial ratios are unavailable in the provided data, limiting fundamental analysis.
The outlook for SHY is cautious due to bearish technical signals and a lack of current fundamental data. Investment opportunities may arise from dividend income, but risks include market volatility and reliance on broader economic conditions. Investors should seek updated financials for a complete assessment.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →SHY provides exposure to U.S. Treasury bonds with remaining maturities between one and three years. It is a low-risk, highly liquid ETF designed for capital preservation and short-term income, featuring 2026 top holdings across various Treasury Notes.
Read more on SHY →